Sign In
Section Navigation
Common TitleARTEMIS
Official Title Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of Darunavir/Ritonavir (TMC114/r) in Treatment- Naive HIV-1 Infected Patients.
Phase Phase III
ClinicalTrials.gov NCT00258557
Treatments
Darunavir
Darunavir Prezista

Darunavir

Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)
,
Lopinavir-Ritonavir
Lopinavir-Ritonavir Kaletra

Lopinavir-Ritonavir

Tradename:KaletraOther Names:LPV-RTVClass:Protease Inhibitors (PI)
Categories Resistance/Virological FailureTreatment-Naive
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
  • Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16:99-108.
    [PubMed Abstract]
  • Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-88.
    [PubMed Abstract]
  • Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013;14:49-59.
    [PubMed Abstract]
  • Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-97.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.